25 XP   0   0   10

Can Fite Biopharma Ltd
Buy, Hold or Sell?

Let's analyse Can Fite Biopharma Ltd together

PenkeI guess you are interested in Can Fite Biopharma Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Can Fite Biopharma Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Can Fite Biopharma Ltd

I send you an email if I find something interesting about Can Fite Biopharma Ltd.

Quick analysis of Can Fite Biopharma Ltd (30 sec.)










What can you expect buying and holding a share of Can Fite Biopharma Ltd? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA1.30
Expected worth in 1 year
ILA1.99
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
ILA0.69
Return On Investment
26.5%

For what price can you sell your share?

Current Price per Share
ILA2.60
Expected price per share
ILA2.6 - ILA3
How sure are you?
50%

1. Valuation of Can Fite Biopharma Ltd (5 min.)




Live pricePrice per Share (EOD)

ILA2.60

Intrinsic Value Per Share

ILA-24.00 - ILA-0.52

Total Value Per Share

ILA-22.70 - ILA0.78

2. Growth of Can Fite Biopharma Ltd (5 min.)




Is Can Fite Biopharma Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$6.2m$4.4m$1.7m28.4%

How much money is Can Fite Biopharma Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$7.6m-$10.1m$2.5m33.3%
Net Profit Margin-1,027.5%-1,255.9%--

How much money comes from the company's main activities?

3. Financial Health of Can Fite Biopharma Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#729 / 1016

Most Revenue
#606 / 1016

Most Profit
#288 / 1016

Most Efficient
#813 / 1016

What can you expect buying and holding a share of Can Fite Biopharma Ltd? (5 min.)

Welcome investor! Can Fite Biopharma Ltd's management wants to use your money to grow the business. In return you get a share of Can Fite Biopharma Ltd.

What can you expect buying and holding a share of Can Fite Biopharma Ltd?

First you should know what it really means to hold a share of Can Fite Biopharma Ltd. And how you can make/lose money.

Speculation

The Price per Share of Can Fite Biopharma Ltd is ILA2.6. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Can Fite Biopharma Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Can Fite Biopharma Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA1.30. Based on the TTM, the Book Value Change Per Share is ILA0.17 per quarter. Based on the YOY, the Book Value Change Per Share is ILA-2.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Can Fite Biopharma Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps0.00-0.2%0.00-0.2%-0.01-0.3%-0.01-0.3%-0.01-0.3%
Usd Book Value Change Per Share0.000.0%0.000.0%-0.01-0.3%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.0%-0.01-0.3%0.000.0%0.000.0%
Usd Price Per Share0.01-0.01-0.02-0.04-0.60-
Price to Earnings Ratio-1.63--1.63--3.27--5.11--101.48-
Price-to-Total Gains Ratio15.11-15.11--3.35--6.95--2,507.31-
Price to Book Ratio2.00-2.00-7.43-38.75-160.11-
Price-to-Total Gains Ratio15.11-15.11--3.35--6.95--2,507.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0068744
Number of shares145467
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (145467 shares)66.1841.57
Gains per Year (145467 shares)264.73166.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102652550166156
205295200333322
307947850499488
40105910500665654
50132413150831820
60158815800998986
7018531845011641152
8021182110013301318
9023832375014971484
10026472640016631650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.09.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%4.06.00.040.0%9.011.00.045.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.020.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%4.06.00.040.0%9.011.00.045.0%

Fundamentals of Can Fite Biopharma Ltd

About Can Fite Biopharma Ltd

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Fundamental data was last updated by Penke on 2024-04-20 04:11:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Can Fite Biopharma Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Can Fite Biopharma Ltd earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -1,027.5% means that -10.27 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Can Fite Biopharma Ltd:

  • The MRQ is -1,027.5%. The company is making a huge loss. -2
  • The TTM is -1,027.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,027.5%TTM-1,027.5%0.0%
TTM-1,027.5%YOY-1,255.9%+228.5%
TTM-1,027.5%5Y-1,225.4%+197.9%
5Y-1,225.4%10Y-1,481.0%+255.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,027.5%-199.6%-827.9%
TTM-1,027.5%-213.0%-814.5%
YOY-1,255.9%-279.3%-976.6%
5Y-1,225.4%-438.4%-787.0%
10Y-1,481.0%-605.5%-875.5%
1.1.2. Return on Assets

Shows how efficient Can Fite Biopharma Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • -76.4% Return on Assets means that Can Fite Biopharma Ltd generated -0.76 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Can Fite Biopharma Ltd:

  • The MRQ is -76.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -76.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-76.4%TTM-76.4%0.0%
TTM-76.4%YOY-109.6%+33.2%
TTM-76.4%5Y-103.4%+27.0%
5Y-103.4%10Y-82.6%-20.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-76.4%-13.5%-62.9%
TTM-76.4%-12.9%-63.5%
YOY-109.6%-11.8%-97.8%
5Y-103.4%-14.1%-89.3%
10Y-82.6%-16.0%-66.6%
1.1.3. Return on Equity

Shows how efficient Can Fite Biopharma Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • -122.3% Return on Equity means Can Fite Biopharma Ltd generated -1.22 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Can Fite Biopharma Ltd:

  • The MRQ is -122.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -122.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-122.3%TTM-122.3%0.0%
TTM-122.3%YOY-227.5%+105.2%
TTM-122.3%5Y-353.7%+231.4%
5Y-353.7%10Y-248.2%-105.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-122.3%-16.9%-105.4%
TTM-122.3%-16.1%-106.2%
YOY-227.5%-15.1%-212.4%
5Y-353.7%-19.9%-333.8%
10Y-248.2%-20.9%-227.3%

1.2. Operating Efficiency of Can Fite Biopharma Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Can Fite Biopharma Ltd is operating .

  • Measures how much profit Can Fite Biopharma Ltd makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Can Fite Biopharma Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,246.4%+1,246.4%
TTM-5Y-1,039.2%+1,039.2%
5Y-1,039.2%10Y-1,428.5%+389.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY-1,246.4%-288.4%-958.0%
5Y-1,039.2%-477.4%-561.8%
10Y-1,428.5%-625.6%-802.9%
1.2.2. Operating Ratio

Measures how efficient Can Fite Biopharma Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 12.03 means that the operating costs are 12.03 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Can Fite Biopharma Ltd:

  • The MRQ is 12.030. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.030. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ12.030TTM12.0300.000
TTM12.030YOY13.464-1.435
TTM12.0305Y13.597-1.568
5Y13.59710Y17.305-3.708
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.0303.090+8.940
TTM12.0303.264+8.766
YOY13.4643.783+9.681
5Y13.5975.679+7.918
10Y17.3057.894+9.411

1.3. Liquidity of Can Fite Biopharma Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Can Fite Biopharma Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.90 means the company has 4.90 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Can Fite Biopharma Ltd:

  • The MRQ is 4.905. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.905. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.905TTM4.9050.000
TTM4.905YOY3.660+1.245
TTM4.9055Y5.101-0.196
5Y5.10110Y5.185-0.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9053.914+0.991
TTM4.9054.220+0.685
YOY3.6605.388-1.728
5Y5.1016.045-0.944
10Y5.1856.406-1.221
1.3.2. Quick Ratio

Measures if Can Fite Biopharma Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 2.30 means the company can pay off 2.30 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Can Fite Biopharma Ltd:

  • The MRQ is 2.299. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.299. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.299TTM2.2990.000
TTM2.299YOY1.999+0.300
TTM2.2995Y1.996+0.303
5Y1.99610Y1.021+0.975
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2993.572-1.273
TTM2.2993.998-1.699
YOY1.9995.390-3.391
5Y1.9965.969-3.973
10Y1.0216.287-5.266

1.4. Solvency of Can Fite Biopharma Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Can Fite Biopharma Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Can Fite Biopharma Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.38 means that Can Fite Biopharma Ltd assets are financed with 37.5% credit (debt) and the remaining percentage (100% - 37.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Can Fite Biopharma Ltd:

  • The MRQ is 0.375. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.375. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.375TTM0.3750.000
TTM0.375YOY0.518-0.143
TTM0.3755Y0.488-0.113
5Y0.48810Y0.502-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3750.336+0.039
TTM0.3750.334+0.041
YOY0.5180.269+0.249
5Y0.4880.366+0.122
10Y0.5020.390+0.112
1.4.2. Debt to Equity Ratio

Measures if Can Fite Biopharma Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 60.0% means that company has 0.60 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Can Fite Biopharma Ltd:

  • The MRQ is 0.600. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.600. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.600TTM0.6000.000
TTM0.600YOY1.076-0.476
TTM0.6005Y2.195-1.595
5Y2.19510Y1.701+0.494
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6000.382+0.218
TTM0.6000.396+0.204
YOY1.0760.335+0.741
5Y2.1950.434+1.761
10Y1.7010.465+1.236

2. Market Valuation of Can Fite Biopharma Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Can Fite Biopharma Ltd generates.

  • Above 15 is considered overpriced but always compare Can Fite Biopharma Ltd to the Biotechnology industry mean.
  • A PE ratio of -1.63 means the investor is paying -1.63 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Can Fite Biopharma Ltd:

  • The EOD is -1.632. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.632. Based on the earnings, the company is expensive. -2
  • The TTM is -1.632. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.632MRQ-1.6320.000
MRQ-1.632TTM-1.6320.000
TTM-1.632YOY-3.266+1.634
TTM-1.6325Y-5.108+3.476
5Y-5.10810Y-101.483+96.375
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.632-2.259+0.627
MRQ-1.632-2.569+0.937
TTM-1.632-2.664+1.032
YOY-3.266-4.120+0.854
5Y-5.108-6.258+1.150
10Y-101.483-6.171-95.312
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Can Fite Biopharma Ltd:

  • The EOD is -1.476. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.476. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.476. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.476MRQ-1.4760.000
MRQ-1.476TTM-1.4760.000
TTM-1.476YOY-3.074+1.598
TTM-1.4765Y-6.109+4.633
5Y-6.10910Y-35.404+29.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.476-2.924+1.448
MRQ-1.476-3.246+1.770
TTM-1.476-3.488+2.012
YOY-3.074-5.620+2.546
5Y-6.109-8.315+2.206
10Y-35.404-8.826-26.578
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Can Fite Biopharma Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.00 means the investor is paying 2.00 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Can Fite Biopharma Ltd:

  • The EOD is 1.996. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.996. Based on the equity, the company is underpriced. +1
  • The TTM is 1.996. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.996MRQ1.9960.000
MRQ1.996TTM1.9960.000
TTM1.996YOY7.430-5.434
TTM1.9965Y38.746-36.750
5Y38.74610Y160.106-121.360
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9961.851+0.145
MRQ1.9962.090-0.094
TTM1.9962.095-0.099
YOY7.4302.844+4.586
5Y38.7463.466+35.280
10Y160.1063.815+156.291
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Can Fite Biopharma Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1720.1720%-2.505+1556%0.108+59%-0.262+252%
Book Value Per Share--1.3031.3030%1.131+15%1.565-17%1.974-34%
Current Ratio--4.9054.9050%3.660+34%5.101-4%5.185-5%
Debt To Asset Ratio--0.3750.3750%0.518-28%0.488-23%0.502-25%
Debt To Equity Ratio--0.6000.6000%1.076-44%2.195-73%1.701-65%
Dividend Per Share----0%-0%-0%-0%
Eps---1.593-1.5930%-2.572+61%-3.006+89%-2.797+76%
Free Cash Flow Per Share---1.761-1.7610%-2.733+55%-2.555+45%-2.321+32%
Free Cash Flow To Equity Per Share--0.1460.1460%-1.083+839%0.599-76%0.252-42%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.522--------
Intrinsic Value_10Y_min---24.002--------
Intrinsic Value_1Y_max---1.843--------
Intrinsic Value_1Y_min---2.543--------
Intrinsic Value_3Y_max---4.172--------
Intrinsic Value_3Y_min---7.567--------
Intrinsic Value_5Y_max---4.857--------
Intrinsic Value_5Y_min---12.471--------
Market Cap3892537958.400-21%4716214081.8004716214081.8000%12575891865.600-62%24927265160.040-81%341113606667.700-99%
Net Profit Margin---10.275-10.2750%-12.559+22%-12.254+19%-14.810+44%
Operating Margin----0%-12.4640%-10.3920%-14.2850%
Operating Ratio--12.03012.0300%13.464-11%13.597-12%17.305-30%
Pb Ratio1.9960%1.9961.9960%7.430-73%38.746-95%160.106-99%
Pe Ratio-1.6320%-1.632-1.6320%-3.266+100%-5.108+213%-101.483+6117%
Price Per Share2.6000%2.6002.6000%8.400-69%16.540-84%227.790-99%
Price To Free Cash Flow Ratio-1.4760%-1.476-1.4760%-3.074+108%-6.109+314%-35.404+2299%
Price To Total Gains Ratio15.1100%15.11015.1100%-3.353+122%-6.953+146%-2507.314+16694%
Quick Ratio--2.2992.2990%1.999+15%1.996+15%1.021+125%
Return On Assets---0.764-0.7640%-1.096+43%-1.034+35%-0.826+8%
Return On Equity---1.223-1.2230%-2.275+86%-3.537+189%-2.482+103%
Total Gains Per Share--0.1720.1720%-2.505+1556%0.108+59%-0.262+252%
Usd Book Value--6247377.0926247377.0920%4475135.409+40%6414093.899-3%7921043.592-21%
Usd Book Value Change Per Share--0.0000.0000%-0.007+1556%0.000+59%-0.001+252%
Usd Book Value Per Share--0.0030.0030%0.003+15%0.004-17%0.005-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.0040%-0.007+61%-0.008+89%-0.007+76%
Usd Free Cash Flow---8447918.855-8447918.8550%-10817579.107+28%-10409893.471+23%-6577723.850-22%
Usd Free Cash Flow Per Share---0.005-0.0050%-0.007+55%-0.007+45%-0.006+32%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%-0.003+839%0.002-76%0.001-42%
Usd Market Cap10291870.362-21%12469670.03212469670.0320%33250658.093-62%65907689.083-81%901904376.029-99%
Usd Price Per Share0.0070%0.0070.0070%0.022-69%0.044-84%0.602-99%
Usd Profit---7639352.350-7639352.3500%-10180132.494+33%-10898035.477+43%-10296329.745+35%
Usd Revenue--743520.932743520.9320%810567.907-8%1040929.305-29%1020439.606-27%
Usd Total Gains Per Share--0.0000.0000%-0.007+1556%0.000+59%-0.001+252%
 EOD+0 -2MRQTTM+0 -0YOY+26 -65Y+20 -1210Y+19 -13

3.2. Fundamental Score

Let's check the fundamental score of Can Fite Biopharma Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.632
Price to Book Ratio (EOD)Between0-11.996
Net Profit Margin (MRQ)Greater than0-10.275
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.299
Current Ratio (MRQ)Greater than14.905
Debt to Asset Ratio (MRQ)Less than10.375
Debt to Equity Ratio (MRQ)Less than10.600
Return on Equity (MRQ)Greater than0.15-1.223
Return on Assets (MRQ)Greater than0.05-0.764
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Can Fite Biopharma Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.546
Ma 20Greater thanMa 502.795
Ma 50Greater thanMa 1002.702
Ma 100Greater thanMa 2002.679
OpenGreater thanClose2.600
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets9,989
Total Liabilities3,746
Total Stockholder Equity6,243
 As reported
Total Liabilities 3,746
Total Stockholder Equity+ 6,243
Total Assets = 9,989

Assets

Total Assets9,989
Total Current Assets9,908
Long-term Assets81
Total Current Assets
Cash And Cash Equivalents 4,278
Short-term Investments 4,644
Other Current Assets 78
Total Current Assets  (as reported)9,908
Total Current Assets  (calculated)9,000
+/- 908
Long-term Assets
Property Plant Equipment 81
Long-term Assets  (as reported)81
Long-term Assets  (calculated)81
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,020
Long-term Liabilities1,726
Total Stockholder Equity6,243
Total Current Liabilities
Accounts payable 427
Total Current Liabilities  (as reported)2,020
Total Current Liabilities  (calculated)427
+/- 1,593
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt40
Long-term Liabilities  (as reported)1,726
Long-term Liabilities  (calculated)40
+/- 1,686
Total Stockholder Equity
Total Stockholder Equity (as reported)6,243
Total Stockholder Equity (calculated)0
+/- 6,243
Other
Common Stock Shares Outstanding 1,813,928
Net Invested Capital 6,243
Net Working Capital 7,888
Property Plant and Equipment Gross 344



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
2,711
1,280
37,087
41,761
48,935
21,862
20,101
18,546
18,660
6,109
23,105
39,667
17,633
10,167
7,832
7,952
8,175
9,523
20,253
9,283
9,989
9,9899,28320,2539,5238,1757,9527,83210,16717,63339,66723,1056,10918,66018,54620,10121,86248,93541,76137,0871,2802,711
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
22,928
39,508
17,566
10,122
6,664
7,903
7,144
9,400
20,068
9,157
9,908
9,9089,15720,0689,4007,1447,9036,66410,12217,56639,50822,9280000000000
       Cash And Cash Equivalents 
1,916
659
34,729
9,009
45,720
19,963
18,991
17,506
0
4,278
20,767
36,091
16,945
8,112
3,497
3,615
2,697
8,268
4,390
2,978
4,278
4,2782,9784,3908,2682,6973,6153,4978,11216,94536,09120,7674,278017,50618,99119,96345,7209,00934,7296591,916
       Short-term Investments 
0
0
0
28,077
0
0
0
0
0
0
0
0
0
0
0
273
64
75
14,749
5,001
4,644
4,6445,00114,74975642730000000000028,077000
       Net Receivables 
45
31
264
3,077
235
133
131
135
0
121
201
272
62
22
66
41
651
0
0
0
0
00006514166226227220112101351311332353,0772643145
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
63
966
49
1,031
123
185
126
81
811261851231,03149966630000000000000
       Property Plant Equipment 
670
574
1,697
1,598
1,283
1,029
662
490
278
159
143
133
61
40
28
47
118
123
185
126
81
81126185123118472840611331431592784906621,0291,2831,5981,697574670
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
915
0
0
0
0
0
0
00000091500000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
34
26
7
10
5
2
912
0
0
0
0
00009122510726340000000000
> Total Liabilities 
642
3,087
1,258
3,421
10,231
7,068
6,615
5,474
6,133
8,754
7,580
12,967
7,169
6,293
4,778
4,937
7,298
3,449
5,871
4,811
3,746
3,7464,8115,8713,4497,2984,9374,7786,2937,16912,9677,5808,7546,1335,4746,6157,06810,2313,4211,2583,087642
   > Total Current Liabilities 
626
3,070
1,177
3,339
10,216
7,026
4,719
3,943
5,150
8,686
7,451
5,774
1,781
3,068
1,754
3,119
3,271
1,269
2,730
2,502
2,020
2,0202,5022,7301,2693,2713,1191,7543,0681,7815,7747,4518,6865,1503,9434,7197,02610,2163,3391,1773,070626
       Accounts payable 
156
183
231
2,137
2,663
2,610
647
516
0
2,821
2,056
1,024
463
1,249
427
1,071
2,156
561
954
896
427
4278969545612,1561,0714271,2494631,0242,0562,82105166472,6102,6632,137231183156
       Other Current Liabilities 
336
238
944
1,202
7,553
4,416
4,072
3,427
5,150
5,865
5,395
4,750
220
886
330
926
1,079
334
818
783
0
07838183341,0799263308862204,7505,3955,8655,1503,4274,0724,4167,5531,202944238336
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,790
2,981
1,818
4,027
2,180
3,141
2,309
1,726
1,7262,3093,1412,1804,0271,8182,9813,7900000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75
67
124
62
40
406212467750000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,617
2,025
0
0
0
0
0
0
0000002,0252,6170000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
936
1,172
957
0
0
0
0
0
0
0000009571,172936000000000000
> Total Stockholder Equity
2,069
0
35,829
38,340
38,704
14,794
13,486
13,072
10,306
0
13,226
25,240
10,335
3,865
3,054
3,015
877
6,074
14,382
4,472
6,243
6,2434,47214,3826,0748773,0153,0543,86510,33525,24013,226010,30613,07213,48614,79438,70438,34035,82902,069
   Common Stock
152
152
1,279
1,588
1,908
1,908
2,120
2,309
10,306
2,734
4,037
5,441
1,804
1,783
2,123
2,635
8,225
33,036
60,654
0
0
0060,65433,0368,2252,6352,1231,7831,8045,4414,0372,73410,3062,3092,1201,9081,9081,5881,279152152
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000
   Capital Surplus 000000000000000000000
   Treasury Stock0000000-3,628-3,628-3,628-3,628-5,805000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
25,262
25,790
6,896
12,605
15,489
6,927
1,127
1,127
1,127
1,127
0
01,1271,1271,1271,1276,92715,48912,6056,89625,79025,2620000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue743
Cost of Revenue--
Gross Profit-743
 
Operating Income (+$)
Gross Profit-
Operating Expense-8,938
Operating Income-8,195-8,938
 
Operating Expense (+$)
Research Development5,983
Selling General Administrative2,955
Selling And Marketing Expenses-
Operating Expense8,9388,938
 
Net Interest Income (+$)
Interest Income506
Interest Expense--
Other Finance Cost-14
Net Interest Income492
 
Pretax Income (+$)
Operating Income-8,195
Net Interest Income492
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-7,634-8,264
EBIT - interestExpense = 0
-7,634
-7,634
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--7,634
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-7,634
Tax Provision-0
Net Income From Continuing Ops-7,634-7,634
Net Income-7,634
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net69-492
 

Technical Analysis of Can Fite Biopharma Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Can Fite Biopharma Ltd. The general trend of Can Fite Biopharma Ltd is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Can Fite Biopharma Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Can Fite Biopharma Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.7 < 3 < 3.

The bearish price targets are: 2.6 > 2.6 > 2.6.

Tweet this
Can Fite Biopharma Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Can Fite Biopharma Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Can Fite Biopharma Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Can Fite Biopharma Ltd. The current macd is -0.01870078.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Can Fite Biopharma Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Can Fite Biopharma Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Can Fite Biopharma Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Can Fite Biopharma Ltd Daily Moving Average Convergence/Divergence (MACD) ChartCan Fite Biopharma Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Can Fite Biopharma Ltd. The current adx is 11.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Can Fite Biopharma Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Can Fite Biopharma Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Can Fite Biopharma Ltd. The current sar is 2.96164203.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Can Fite Biopharma Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Can Fite Biopharma Ltd. The current rsi is 39.55. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Can Fite Biopharma Ltd Daily Relative Strength Index (RSI) ChartCan Fite Biopharma Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Can Fite Biopharma Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Can Fite Biopharma Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Can Fite Biopharma Ltd Daily Stochastic Oscillator ChartCan Fite Biopharma Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Can Fite Biopharma Ltd. The current cci is -193.5483871.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Can Fite Biopharma Ltd Daily Commodity Channel Index (CCI) ChartCan Fite Biopharma Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Can Fite Biopharma Ltd. The current cmo is -36.21051392.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Can Fite Biopharma Ltd Daily Chande Momentum Oscillator (CMO) ChartCan Fite Biopharma Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Can Fite Biopharma Ltd. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Can Fite Biopharma Ltd Daily Williams %R ChartCan Fite Biopharma Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Can Fite Biopharma Ltd.

Can Fite Biopharma Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Can Fite Biopharma Ltd. The current atr is 0.12502785.

Can Fite Biopharma Ltd Daily Average True Range (ATR) ChartCan Fite Biopharma Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Can Fite Biopharma Ltd. The current obv is -43,808,654.

Can Fite Biopharma Ltd Daily On-Balance Volume (OBV) ChartCan Fite Biopharma Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Can Fite Biopharma Ltd. The current mfi is 55.57.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Can Fite Biopharma Ltd Daily Money Flow Index (MFI) ChartCan Fite Biopharma Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Can Fite Biopharma Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Can Fite Biopharma Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Can Fite Biopharma Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.546
Ma 20Greater thanMa 502.795
Ma 50Greater thanMa 1002.702
Ma 100Greater thanMa 2002.679
OpenGreater thanClose2.600
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Can Fite Biopharma Ltd with someone you think should read this too:
  • Are you bullish or bearish on Can Fite Biopharma Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Can Fite Biopharma Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Can Fite Biopharma Ltd

I send you an email if I find something interesting about Can Fite Biopharma Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Can Fite Biopharma Ltd.

Receive notifications about Can Fite Biopharma Ltd in your mailbox!